Table 1.
Characteristics of all patients with COPD, and by sex
| All patients (n=3,141) | Male (n=2,017) | Female (n=1,124) | |
|---|---|---|---|
| Age, years | 63.1 (9.2) | 63.9 (9.1) | 61.7 (9.3) |
| BMI, kg/m2 | 26.7 (5.8) | 26.6 (5.3) | 26.9 (6.8) |
| Month since first COPD symptoms | 130.0 (85.2) | 127.0 (86.2) | 124.2 (83.6) |
| FEV1 | |||
| Pre-bronchodilator, % predicted | 34.6 (10.1) | 33.6 (10.0) | 36.4 (10.1) |
| Reversibility, % predicted | 5.5 (5.9) | 5.1 (5.3) | 6.4 (6.7) |
| Post-bronchodilator, % predicted | 40.1 (12.2) | 38.7 (11.8) | 42.8 (12.5) |
| Pre-bronchodilator FEV1/FVC ratio, % | 47.2 (10.6) | 46.1 (10.5) | 49.2 (10.6) |
| COPD severity (GOLD grade), n (%) | |||
| II (moderate) | 649 (20.7) | 340 (16.9) | 309 (27.5) |
| III (severe) | 1,770 (56.4) | 1,159 (57.5) | 611 (54.4) |
| IV (very severe) | 697 (22.2) | 506 (25.1) | 191 (17.0) |
| Exacerbations during previous year, n (%) | |||
| 1 | 1,886 (60.0) | 1,264 (62.7) | 622 (55.3) |
| 2 | 785 (25.0) | 486 (24.1) | 299 (26.6) |
| 3 | 258 (8.2) | 138 (6.8) | 120 (10.7) |
| 4 | 120 (3.8) | 74 (3.7) | 46 (4.1) |
| >4 | 92 (2.9) | 55 (2.7) | 37 (3.3) |
| Smoking history | |||
| Median, pack-years (range) | 40.0 (10.0–258.0) | 44.0 (10.0–258.0) | 38.0 (10.0–175.0) |
| Current smoker, n (%) | 1,280 (40.8) | 772 (38.3) | 508 (45.2) |
| Ex-smoker, n (%) | 1,861 (59.2) | 1,245 (61.7) | 616 (54.8) |
| Mean SGRQ total score (range) | 55.6 (6.2–100.0) | 54.4 (6.2–100.0) | 57.6 (10.6–100.0) |
| Mean reliever use, inhalations per day (range) | 4.3 (0.0–33.8) | 4.2 (0.0–33.8) | 4.4 (0.0–29.9) |
| Sleep symptom score (0–4) | 1.04 | 1.05 | 1.01 |
| Number of COPD medications at study entry, n (%)a | |||
| 0 | 803 (25.6) | 495 (24.5) | 308 (27.4) |
| 1 | 722 (23.0) | 468 (23.2) | 254 (22.6) |
| 2 | 987 (31.4) | 622 (30.8) | 365 (32.5) |
| 3 | 621 (19.8) | 425 (21.1) | 196 (17.4) |
| Comorbidities, n (%)b | |||
| 0 | 1,124 (35.8) | 751 (37.2) | 373 (33.2) |
| 1 | 1,119 (35.6) | 739 (36.6) | 380 (33.8) |
| 2 | 622 (19.8) | 374 (18.5) | 248 (22.1) |
| >2 | 276 (8.8) | 153 (7.6) | 123 (10.9) |
Notes: Data reported as mean and standard deviation, unless stated otherwise. GOLD COPD grades are defined as: grade II = post-bronchodilator FEV1 50%–80% of predicted; grade III = post-bronchodilator FEV1 30%–50% of predicted; and grade IV = post-bronchodilator FEV1<30% of predicted.
Number of COPD maintenance medications at study entry: 0= no maintenance treatment with LA (long-acting β2-agonists, long-acting antimuscarinics, and theophylline), ICS, or other daily treatments (ie, short-acting [β2-agonist or antimuscarinic] bronchodilators only), 1= one maintenance medication, 2= two maintenance medications, 3= three or more maintenance medications
comorbidities – number of comorbidity classes (cardiac-related morbidities [ischemic cardiovascular disease and arteriosclerosis], hypertension, diabetes, depression/anxiety, gastroesophageal reflux disease). Data from.15–17
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LA, long-acting bronchodilators; SGRQ, St George’s Respiratory Questionnaire.